Mai 2024

Boukovala, M.; Modest, D.P.; Ricard, I.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Peveling Genannt Reddemann, C.; Graeven, U.; Schuch, G.; Schwaner, I.; Heinrich, K.; Neumann, J.; Jung, A.; Held, S.; Stintzing, S.; Heinemann, V.; Michl, M. (2024): Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110). ESMO Open, 9 (5): 103374. ISSN 20597029

April 2026

Schuebbe, G.-E.; Xu, Y.; Lindner, L.H.; Di Gioia, D.; Abdel-Rahman, S.; Kunz, W.G.; Roshchyna, T.; Fenderle, R.; Bücklein, V.; Reichardt, P.; Pink, D.; Flörcken, A.; Ott, O.; Fietkau, R.; Kampmann, E.; von Bergwelt-Baildon, M.; Kasper, B.; Issels, R. (2026): A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trial. ESMO Open, 11 (4): 106921. ISSN 2059-7029